1. Home
  2. EDAP vs NTHI Comparison

EDAP vs NTHI Comparison

Compare EDAP & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo EDAP TMS S.A.

EDAP

EDAP TMS S.A.

HOLD

Current Price

$4.32

Market Cap

128.9M

Sector

Health Care

ML Signal

HOLD

NTHI

NeOnc Technologies Holdings Inc.

HOLD

Current Price

$4.55

Market Cap

139.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EDAP
NTHI
Founded
1979
2008
Country
France
United States
Employees
N/A
5
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
128.9M
139.1M
IPO Year
1998
N/A

Fundamental Metrics

Financial Performance
Metric
EDAP
NTHI
Price
$4.32
$4.55
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$10.00
$15.00
AVG Volume (30 Days)
30.0K
46.6K
Earning Date
05-07-2026
05-19-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$70,527,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$6.13
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.63
N/A
52 Week Low
$1.21
$3.20
52 Week High
$5.05
$12.99

Technical Indicators

Market Signals
Indicator
EDAP
NTHI
Relative Strength Index (RSI) 61.10 40.36
Support Level $3.18 $4.49
Resistance Level $4.38 $5.90
Average True Range (ATR) 0.26 0.45
MACD -0.00 -0.02
Stochastic Oscillator 67.39 23.33

Price Performance

Historical Comparison
EDAP
NTHI

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its globalized activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

About NTHI NeOnc Technologies Holdings Inc.

NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.

Share on Social Networks: